Home › Research › Lewy body dementia
MAPT mutations, tauopathy, and mechanisms of neurodegeneration
Strang KH, Golde TE, Giasson BI.. Laboratory investigation; a journal of technical methods and pathology, 2019-02-11
Topic: Brain proteins, microglia and lab models
Plain-language summary
In multiple neurodegenerative diseases, including Alzheimer's disease (AD), a prominent pathological feature is the aberrant aggregation and inclusion formation of the microtubule-associated protein tau. Because of the pathological association, these disorders are often referred to as tauopathies. Mutations in the MAPT gene that encodes tau can cause frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), providing the clearest evidence that tauopathy plays a causal role in neurodegeneration. However, large gaps in our knowledge remain regarding how various FTDP-17-linked tau mutations promote tau aggregation and neurodegeneration, and, more generally, how the tauopathy is linked to neurodegeneration. Herein, we review what is known about how FTDP-17-linked pathogenic MAPT mutations cause disease, with a major focus on the prion-like properties of wild-type and mutant tau proteins. The hypothesized mechanisms by which mutations in the MAPT gene promote tauopathy are quite varied and may not provide definitive insights into how tauopathy arises in the absence of mutation. Further, differences in the ability of tau and mutant tau proteins to support prion-like propagation in various model systems raise questions about the generalizability of this mechanism in various tauopathies. Notably, understanding the mechanisms of tauopathy induction and spread and tau-induced neurodegeneration has important implications for tau-targeting therapeutics.
What this study adds
Evidence grade: Low
This is a narrative review. This review examines how FTDP-17-linked MAPT mutations cause tauopathy and neurodegeneration, focusing on the prion-like properties of wild-type and mutant tau. It notes large gaps in knowledge and questions the generalizability of prion-like propagation across tauopathies, reporting no treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Strang, K. H., Golde, T. E., & Giasson, B. I. (2019). MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Laboratory investigation; a journal of technical methods and pathology. https://doi.org/10.1038/s41374-019-0197-x
Vancouver
Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Laboratory investigation; a journal of technical methods and pathology. 2019. doi:10.1038/s41374-019-0197-x. PMID: 30742061.
BibTeX
@article{strang2019-30742061,
author = {Strang, K. H. and Golde, T. E. and Giasson, B. I.},
title = {{MAPT mutations, tauopathy, and mechanisms of neurodegeneration}},
journal = {Laboratory investigation; a journal of technical methods and pathology},
year = {2019},
doi = {10.1038/s41374-019-0197-x},
pmid = {30742061},
url = {https://doi.org/10.1038/s41374-019-0197-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- However, large gaps in our knowledge remain regarding how various FTDP-17-linked tau mutations promote tau aggregation and neurodegeneration, and, more generally, how the tauopathy is linked to neurodegeneration.
- Herein, we review what is known about how FTDP-17-linked pathogenic MAPT mutations cause disease, with a major focus on the prion-like properties of wild-type and mutant tau proteins.
- The hypothesized mechanisms by which mutations in the MAPT gene promote tauopathy are quite varied and may not provide definitive insights into how tauopathy arises in the absence of mutation.
- Further, differences in the ability of tau and mutant tau proteins to support prion-like propagation in various model systems raise questions about the generalizability of this mechanism in various tauopathies.
- Notably, understanding the mechanisms of tauopathy induction and spread and tau-induced neurodegeneration has important implications for tau-targeting therapeutics.
Why it matters
This review examines how FTDP-17-linked MAPT mutations cause tauopathy and neurodegeneration, focusing on the prion-like properties of wild-type and mutant tau. It notes large gaps in knowledge and questions the generalizability of prion-like propagation across tauopathies, reporting no treatment, cure, or prevention.
Study details
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Laboratory investigation; a journal of technical methods and pathology) |
| Journal's citation record | 2 / 4 | Laboratory Investigation: journal h-index 176 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 424 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 47.1 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 4 / 6 | Cited 19.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 13 other studies in this library |
| Still being cited | 4 / 4 | Cited 226 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Benoit I. Giasson: h-index 87 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Florida: institution h-index 1,303 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30742061) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41374-019-0197-x
- PubMed: 30742061
- Original source →
- Free full text: Laboratory Investigation →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Later studies that cite this one
13 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Lewy body dementia from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.